The 36‐kDa protein retains antiangiogenic activity, whereas the 29‐kDa protein loses it.11 We have recently shown that this degradation is enhanced in the presence of cancer cells, which indicates that the VASH1 protein secreted by ECs is inactivated in the tumor microenvironment.24 Here, we applied a VASH1 ELISA assay, which detects antiangiogenic 44‐ and 36‐kDa protein, but not inactive 29‐kDa protein,11, 23 and evaluated the potential value of preoperative plasma VASH1 concentration as a prognostic factor in patients with resected lung cancer. This evidence concerns the gene VASH1 and lung carcinoma.